Vifor Pharma
Iron deficiency / nephrology therapeutics (part of CSL group since 2022)
Subsidiary of CSL Limited (CSL) · Switzerland
Assets
(7 total)
7Total Assets
5Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
Difelikefalin(Korsuva) | Approved | Kappa-opioid receptor (agonist, peripherally restricted)Peptide | Chronic Kidney Disease |
Extended-release calcifediol(Rayaldee) | Approved | Vitamin D receptor (VDR), via conversion to calcitriolSmall molecule | Chronic Kidney Disease Secondary Hyperparathyroidism |
Ferric carboxymaltose(Injectafer / Ferinject) | Approved | Iron repletionOther | Heart FailureChronic Kidney DiseaseIron Deficiency Anemia |
sparsentan(Filspari) | Approved | Angiotensin II receptor type 1 (AT1R) + Endothelin receptor type A (ETA)Small molecule | Focal Segmental GlomerulosclerosisIgA Nephropathy |
Sucroferric oxyhydroxide(Velphoro) | Approved | Dietary phosphateSmall molecule | Chronic Kidney DiseaseHyperphosphatemia |
Patiromer(Veltassa) | Phase 3 | Gastrointestinal potassium binderSmall molecule | Chronic Kidney Disease |
Avacopan(Tavneos) | Phase 2 | Complement C5a receptor 1 (C5aR1/CD88)Small molecule | Chronic Kidney Disease |
Upcoming events
(5 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
March 2027 (1)
sparsentan · FilspariPhase 2Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome
Est. primary completion 2027-03-12 · NCT05003986 · CT.gov ↗
What to watch
July 2027 (1)
Est. primary completion 2027-07-18 · NCT06321601 · CT.gov ↗
What to watch
October 2027 (1)
Extended-release calcifediol · RayaldeePhase 2CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
Est. primary completion 2027-10 · NCT07494045 · CT.gov ↗
What to watch
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
4 August 2026WithdrawalAvacopanEuropean Commission revokes the EU marketing authorisation of Tavneos (Article 20 review of ADVOCATE data handling)
EU, EMA/EC · European Commission · Source ↗
30 April 2026Withdrawal proposedAvacopanFDA proposes to withdraw approval of TAVNEOS (NDA held by ChemoCentryx, an Amgen company); opportunity for a hearing
US, FDA · FDA (CDER) · Source ↗
US, FDA · Source ↗
US, FDA · Source ↗
Financial reports
No financial reports recorded.